ACG Wealth’s Regeneron Pharmaceuticals REGN Stock Holding History

ACG Wealth’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-50	Closed	-$30K	–	832
2022 Q2	$30K	Buy	+50	New	+$32.5K	0.01%	513

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACG Wealth's REGN Position: Q3 2022 in Review

ACG Wealth sold out of Regeneron Pharmaceuticals (REGN) in Q3 2022, closing a stake of 50 shares — an estimated $30K sold.

ACG Wealth first reported a position in REGN in Q2 2022 and held it in 1 quarter. The position peaked at $30K in Q2 2022. 1,080 funds tracked by Wall St. Rank hold REGN as of Q3 2022.

ACG Wealth reported no remaining Regeneron Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
ACG Wealth sold 50 Regeneron Pharmaceuticals shares in Q3 2022, an estimated $30K.
ACG Wealth first reported a position in Regeneron Pharmaceuticals in Q2 2022 and held it in 1 quarter.
ACG Wealth's Regeneron Pharmaceuticals position peaked at $30K in Q2 2022.
1,080 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2022.

Based on ACG Wealth's 13F filing for Q3 2022, filed 3 Nov 2022.